Skip to content

Home
Artificial intelligence
Biotechnology
Genetics
Medical Technology

Home
Uncategorized
Exelixis cut to Underperform at BofA on valuation and lack of catalysts

Exelixis cut to Underperform at BofA on valuation and lack of catalysts

Jan 5, 2026

Post navigation

FDA cites severe liver injury risk, unclear benefit behind Sanofi’s MS drug rejection

Tiger BioSciences Announces Launch of New Dermatology Division, Expanding Access to Advanced Wound Care and Aesthetic Solutions

PR Newswire
GlobeNewswire

Contact
Privacy Policy

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Search for: